Edition:
United States

Codexis Inc (CDXS.O)

CDXS.O on Nasdaq

7.35USD
17 Oct 2017
Change (% chg)

$-0.30 (-3.92%)
Prev Close
$7.65
Open
$7.60
Day's High
$7.67
Day's Low
$7.30
Volume
163,034
Avg. Vol
166,829
52-wk High
$7.95
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

Codexis Inc, Nestlé Health Science enter strategic collaboration​
Thursday, 12 Oct 2017 08:00am EDT 

Oct 12 (Reuters) - Codexis Inc :Codexis Inc - ‍co, Nestlé Health Science enter strategic collaboration​.Codexis Inc - ‍Codexis receives an upfront payment of $14 million and potential milestones and royalties depending on product success for deal​.Codexis Inc - deal ‍includes an option for global development of CDX-6114 for PKU​.Codexis Inc - ‍Codexis will be responsible for clinical development costs for CDX-6114 up to and including Phase 1 in healthy volunteers​.Codexis - after ‍phase 1, Nestlé health science will have option to obtain exclusive global license to CDX-6114.Codexis - after ‍Phase 1, Nestlé health science will be responsible for all future development and commercialization of CDX-6114​.  Full Article

Codexis Q2 loss per share $0.13
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Codexis Inc :Codexis reports financial results for the second quarter of 2017.Q2 non-GAAP loss per share $0.09.Q2 loss per share $0.13.Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.Codexis Inc - total revenues for Q2 of 2017 were $10.3 million compared with $16.0 million for Q2 of 2016.Codexis Inc - affirms 2017 total revenue guidance.Codexis Inc - increases full year product sales and gross margin guidance.Sees 2017 product sales guidance of between $25 million and $27 million reflects an increase of 63% to 76% over 2016.Codexis Inc - increasing guidance of product gross margin to between 40% and 43% for 2017.  Full Article

Codexis ‍wins summary judgment of patent infringement against EnzymeWorks​
Tuesday, 8 Aug 2017 04:38pm EDT 

Aug 9 (Reuters) - Codexis Inc -:Codexis Inc - ‍obtains court order awarding summary judgment of patent infringement against EnzymeWorks​.Codexis Inc - ‍secured federal court order awarding co summary judgment on 10 claims of patent infringement brought in lawsuit against EnzymeWorks Inc​.  Full Article

Codexis, effective as of June 30, entered into loan, security agreement with Western Alliance Bank
Friday, 7 Jul 2017 04:25pm EDT 

July 7 (Reuters) - Codexis Inc ::Codexis Inc - effective as of june 30, 2017 co entered into a loan and security agreement with western alliance bank.Codexis Inc - pursuant to agreement wab agreed to make term loans available to company in a principal amount of up to $10 million - sec filing.Codexis - WAB agreed to make revolving advances available to co in principal amount of up to $5 million, with accounts receivable borrowing base of 80% of eligible accounts.Codexis Inc - company did not draw from credit facility on closing date, and term loans may be funded at company's request prior to june 30, 2018.  Full Article

Codexis reports Q1 non-GAAP loss per share $0.13
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Codexis Inc :Codexis reports financial results for the first quarter of 2017.Q1 non-GAAP loss per share $0.13.Q1 loss per share $0.18.Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Codexis Inc says Codexis is affirming its financial guidance for 2017.FY 2017 earnings per share view $-0.31, revenue view $51.3 million -- Thomson Reuters I/B/E/S.  Full Article

Codexis announces pricing of public offering of common stock
Friday, 7 Apr 2017 09:15am EDT 

Codexis Inc : Codexis announces pricing of public offering of common stock .Says public offering of 5.50 million common shares priced at $4.00 per share.  Full Article

Codexis Q4 loss per share $0.13
Thursday, 9 Mar 2017 04:05pm EST 

Codexis Inc : Codexis reports 2016 fourth quarter and full year financial results . Q4 loss per share $0.13 . Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S . Codexis Inc - total revenues for Q4 of 2016 were $10.0 million . Codexis Inc - research and development (research and development) expenses were $6.0 million for Q4 of 2016 compared with $5.2 million for q4 of 2015 . Codexis Inc- sees 2017 total revenues of $50 million to $53 million . Codexis Inc- sees 2017 product sales of $21 million to $23 million, an increase of 37% to 50% over 2016 . Codexis Inc- sees 2017 gross margin on product sales between 37% and 39% .Codexis inc- sees 2017 total operating expenses for research and development and sg&a to increase by 6% to 8%.  Full Article

Codexis to supply Tate & Lyle proprietary enzyme for food ingredient production
Tuesday, 6 Dec 2016 07:00am EST 

Codexis Inc :Codexis Inc - has entered into an exclusive agreement with Tate & Lyle to supply a proprietary enzyme for use in company's food ingredient production.  Full Article

Codexis reports Q2 adj. earnings per share $0.12
Tuesday, 9 Aug 2016 04:05pm EDT 

Codexis Inc : Codexis reports financial results for the second quarter of 2016 . Q2 earnings per share $0.05 . Sees FY 2016 revenue $46 million to $49 million . Q2 non-GAAP earnings per share $0.12 . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Q2 revenue $16 million versus I/B/E/S view $15.1 million.  Full Article

Codexis reports Q1 loss per share $0.17
Monday, 9 May 2016 04:05pm EDT 

Codexis Inc : Codexis reports financial results for the first quarter of 2016 . Q1 non-GAAP loss per share $0.11 . Q1 loss per share $0.17 . Q1 revenue $8.0 million versus I/B/E/S view $7.5 million .Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Codexis Inc, Nestlé Health Science enter strategic collaboration​

* Codexis Inc - ‍co, Nestlé Health Science enter strategic collaboration​